2013-01-21 15:32:23 - New Pharmaceuticals market report from GlobalData: "Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis"
GlobalData has released its new PharmaPoint Drug Evaluation report, Xeljanz (tofacitinib) (Rheumatoid Arthritis) Forecast and Market Analysis. The RA market is currently very dynamic, with the November 6, 2012 FDA approval of Pfizer's Xeljanz (tofacitinib) and novel oral therapies awaiting approval such as: Eli Lilly's anti-BAFF, tabalumab and JAK1,2 inhibitor, baricitinib, and Rigel/AZ's SYK inhibitor, fostamatinib. These compounds will challenge the current biologics in the attempt to dislodge the stronghold of the TNF inhibitors, if their safety and efficacy profiles are proven once they enter the market.
Pfizer has developed Xeljanz (tofacitinib;formerly known as tasocitinib), an oral, small-molecule inhibitor of JAK3 kinase for the treatment of RA, psoriasis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, transplant rejection, and dry eye
syndrome. Xeljanz (tofacitinib) is the most advanced kinase inhibitor in development for RA and is a first-in-class product. Xeljanz (tofacitinib) targets the JAK pathway, thus disrupting the intracellular signal pathway through which cytokines regulate immune responses.
Full Report Details at
- www.fastmr.com/prod/529859_xeljanz_tofacitinib_rheumatoid_arthri ..
* Overview of RA, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
* Detailed information on Xeljanz (tofacitinib) including product description, safety and efficacy profiles as well as a SWOT analysis.
* Sales forecast for Xeljanz (tofacitinib) for the top eight countries from 2011 to 2022.
* Sales information covered for the US, France, Germany, the UK, Italy, Spain, Japan and Australia.
Reasons to buy
* Understand and capitalize by identifying products that are most likely to ensure a robust return
* Stay ahead of the competition by understanding the changing competitive landscape for rheumatoid arthritis.
* Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
* Make more informed business decisions from insightful and in-depth analysis of Xeljanz (tofacitinib) performance
* Obtain sales forecast for Xeljanz (tofacitinib) from 2011 to 2022 in (the US, France, Germany, the UK, Italy, Spain, Japan and Australia)
Partial Table of Contents:
1 Table of Contents
1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2.2 Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.1.4 Quality of Life
4 Disease Management
5 Competitive Assessment
5.2 Strategic Competitor Assessment
6 Opportunity and Unmet Need
6.2 Unmet Needs
6.2.1 More rheumatologists in the field and physician knowledge of the disease
6.2.2 More cost-effective therapies through oral formulation and biosimilars
6.2.3 The development of predictive tests and discovery of biomarkers
6.2.4 The discovery of curative therapies
6.2.5 Improved drug safety and efficacy profiles
6.3 Gap Analysis
6.4.1 Predictive tools for diagnosis and treatment
6.4.2 Target specificity
7 Pipeline Assessment
7.2 Promising Drugs in Clinical Development
8 Xeljanz (tofacitinib)
8.4 Dosing and Formulation
8.5 Potential Clinical Positioning
8.6 Potential Commercial Positioning
8.7 Pricing and Reimbursement
8.8 SWOT Analysis
9.4 Forecasting Methodology
9.4.1 Diagnosed Rheumatoid Arthritis Patients
9.4.2 Percent Drug-treated Patients
9.4.3 General Pricing Assumptions
9.4.4 Pricing of Pipeline agents
9.5 Physicians and Specialists Included in this Study
9.6 Primary Research - Prescriber Survey
9.7 About the Authors
9.7.2 Global Head of Healthcare
9.8 About GlobalData
9.9 Contact Us
List of Tables
1.1 List of Tables
Table 1: Symptoms of Rheumatoid Arthritis
Table 2: Treatment Guidelines for Rheumatoid Arthritis
Table 3: Top Three Biologics Prescribed for Moderate-Severe Rheumatoid Arthritis by Market
Table 4: Treatment Guidelines for Rheumatoid Arthritis
Table 5: Overall Unmet Needs - Current Level of Attainment
Table 6: Clinical Unmet Needs - Gap Analysis, 2012
Table 7: Rheumatoid Arthritis - Phase Pipeline, 2012
Table 8: Comparison of Therapeutic Classes in Development for RA, 2012
Table 9: Product Profile - Xeljanz (tofacitinib)
Table 10: Clinical Trial Locations by Country for Xeljanz (tofacitinib)
Table 11: ORAL Standard ACR 20 Responses for Xeljanz (tofacitinib) vs. Placebo vs. Humira at Month 6
Table 12: ORAL Step ACR 20, 50, 70 Responses for Xeljanz (tofacitinib) vs. Placebo at Month Six
Table 13: Efficacy Issues Regarding Xeljanz (tofacitinib) Determined by FDA Advisory Panel, May 2012
Table 14: Safety Issues Regarding Xeljanz (tofacitinib) Determined by FDA Advisory Panel, May 2012
Table 15: Xeljanz (tofacitinib) Clinical Trial Mortalities as of September 29, 2011
Table 16: Xeljanz (tofacitinib) SWOT Analysis, 2012
Table 17: Global Sales Forecasts ($m) for Xeljanz (tofacitinib)
Table 18: Physicians Surveyed, By Country
List of Figures
1.2 List of Figures
Figure 1: Healthy and Arthritic Joint with Rheumatoid Arthritis
Full Table of Contents is available at:
GlobalData is a leading provider of global business intelligence including market, competitor, product and customer information. It provides in-depth research, analysis, data and forecasts through a range of interactive online databases, reports and management briefings. GlobalData has a large team of experienced research and analysis, consulting, and marketing experts. It has a global presence, including key offices in the US, Europe and Asia. The group has over 50 years of experience of delivering market intelligence data and analysis and a highly experienced senior management team. View more research from GlobalData at www.fastmr.com/catalog/publishers.aspx?pubid=1015
About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. We represent the world's top research publishers and analysts and provide quick and easy access to the best competitive intelligence available.
For more information about these or related research reports, please visit our website at www.fastmr.com
or call us at 1.800.844.8156.